UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/552,194	10/12/2006	Matthew A. Nugent	701586-53702 8409		
50607 RONALD I. E	7590 10/25/2007 ISENSTEIN		EXAMINER		
100 SUMMER STREET			UNDERDAHL, THANE E		
NIXON PEABODY LLP BOSTON, MA 02110			ART UNIT	PAPER NUMBER	
			1651		
			MAIL DATE	DELIVERY MODE	
			10/25/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
		10/552,194	NUGENT ET AL.	NUGENT ET AL.	
	Office Action Summary	Examiner	Art Unit .		
		Thane Underdahl	1651		
Period fo	The MAILING DATE of this communication app r Reply	ears on the cover sheet wit	the correspondence address	;	
WHIC - Exter after - If NO - Failui Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE is is a sound of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 6(a). In no event, however, may a re rill apply and will expire SIX (6) MONT cause the application to become ABA	ATION. bly be timely filed HS from the mailing date of this communi. NDONED (35 U.S.C. § 133).		
Status					
2a) <u></u> □	Responsive to communication(s) filed on <u>01 Ju</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matte	· ·	its is	
Dispositi	on of Claims				
5)□ 6)□ 7)□ 8)⊠ Applicati 9)□	Claim(s) 1-30 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-30 are subject to restriction and/or example on Papers The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	vn from consideration. election requirement. r. epted or b) objected to b drawing(s) be held in abeyand	ce. See 37 CFR 1.85(a).	12474)	
11)	The oath or declaration is objected to by the Ex				
Priority u	ınder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
2) Notice 3) Information	e of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	Paper No(s	ummary (PTO-413) /Mail Date ormal Patent Application _·		

Application/Control Number: 10/552,194

Art Unit: 1651

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. The groups and the claims they include are as follows:

Group I, claim(s) 1-16 and 23-30, are drawn to a device comprise an extracellular matrix having an internal pH between 4.0 and 6.0 that contains a heparin or heparin related compound that binds a protein and the binding is pH dependant.

Group I, claim(s) 17-22, are drawn to a method for stimulating angiogenesis at a clinically relevant site in a mammal by administering an effective amount of the device from claim 1.

(a) An international or national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those invention involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the CLAIMED INVENTIONS, CONSIDERED AS A WHOLE, MAKES OVER THE PRIOR ART.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because the invention AS CLAIMED is known in the art, see (U.S. Patent # 5,613,982), and thus no special technical feature unites these inventions in a category. The cited patent teaches an ECM based transplant tissue matrix that can contain heparin that inherently binds to fibronectin to enhance vascular growth that can have a pH that is alter alterable with the pH profile of the bound protein (claim 9). The matrix is exposed to a pH between 5.5 and 8 (col 5, lines 55-60).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37

Application/Control Number: 10/552,194

Art Unit: 1651

CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thane Underdahl whose telephone number is (571) 272-9042. The examiner can normally be reached on Monday-Thursday 8:00 to 17:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/552,194

Art Unit: 1651

Thane Underdahl Art Unit 1651

Page 4

Leon B Lankford Jr Primary Examiner Art Unit 1651